UK-CAB 65: BHIVA/BASHH feedback; Treatment as/for prevention

Saturday 21 April 2018

Please note:

This meeting will take place in Edinburgh, to take advantage of the BHIVA/BASHH conference. The meeting will focus on Guidelines feedback, in relation to quality of life: community reps for guidelines will provide feedback.

Programme

09.15-09.30 Arrival, tea and refreshments
09.30-10.00 Welcome and introductions, UK-CAB updates, company pre-meeting
10.00-11.30 Company meeting: MSD
11.30-11.45 BREAK
11.45-12.45 Conference feedback – clinical perspective – Prof. Clifford Leen, Western General Hospital
12.45-14.00 LUNCH
 

14.00-15.30

Treatment as/for prevention

·       2018 BHIVA Pregnancy guidelines – Angelina Namiba

·       TasP for Sexual reproduction health – Aicha Kallo

·       U=U discussion feedback – Longret Kwardem & Sunil Pant

15.30-15.45 BREAK
 

15.45-16.30

Conferences feedback – CROI

BHIVA/BASHH Conference community feedback

Reflection and feedback of the meeting member updates

16.30 Meeting close

Presentations from this meeting

BHIVA BASHH Feedback, slide set 1 of 2 – Prof. Clifford Leen
BHIVA BASHH feedback, slide set 2 0f 2
2018 BHIVA pregnancy guidelines feedback – Angelina Namiba
TasP for Sexual reproduction health– Aicha Kallo
U=U discussion feedback – Longret Kwardem

Background reading

BHIVA guidelines: http://www.bhiva.org/Guidelines.aspx
BHIVA produces a number of guidelines for the clinical management of HIV. You can see all the guidelines here, including the ones that have been updated and will be presented at the BHIVA/BASHH conference.

Breast is best – presentations, debate and discussion
See paper prepared by Angelina for her session on Pregnancy guidelines.

Treatment as prevention:

Prevention access campaign:
“U=U is a simple but hugely important campaign based on a solid foundation of scientific evidence. It has already been successful in influencing public opinion, causing more people with HIV (and their friends and families) to comprehend that they can live long, healthy lives, have children, and never have to worry about passing on their infection to others.”  The Lancet (November, 2017)

The evidence for U=U (Undetectable = Untransmittable): why negligible risk is zero risk

Treatment as prevention from Avert

Here are two videos that talk about ‘combination prevention’ from BHIVA in Liverpool last year.

http://www.bhiva.org/170405ValerieDelpech.aspx

http://www.bhiva.org/170405MonicaDesai.aspx

CROI conference feedback:

Important themes this year included cure-related research; TB coinfection, PrEP and new antiretroviral drugs. As usual, webcasts and conference material are already online. Also, news that after more than a decade in development, the monoclonal antibody ibalizumab has been approved in the US as a treatment for multidrug resistant HIV.

Here are some CROI reports from HIV i-Base:

HTB issue 5 – 14 March 201

HTB issue 6 – 30 March 2018

CROI feedback from NAM

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.

 

Published: May 9, 2017
Last edited: May 1, 2018